Markets

GSK wagers up to $1.3B on a different kind of cancer drug

1 source ·1 article ·3h ago GSK

With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two well-known cancer drivers, EGFR and KRAS.

Covered by 1 outlet

Biopharmadive 1

All coverage · 1 article

BioPharma Dive ·3h ago

GSK wagers up to $1.3B on a different kind of cancer drug

With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two well-known cancer drivers, EGFR and KRAS.

GSK wagers up to $1.3B on a different kind of cancer drug

GSK wagers up to $1.3B on a different kind of cancer drug →

GSK wagers up to $1.3B on a different kind of cancer drug